Loading stock data…
MGTX
$9.21+0.12 (+1.32%)
After Hours$9.21+0.00 (+0.00%)· Last close Jun 9
MeiraGTx Holdings plc, a clinical-stage genetic medicines company, focusing on developing treatments for patients with serious diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
MeiraGTx Holdings plc in the Healthcare sector is trading at $9.21 with a market capitalization of $870M. Wall Street consensus targets $28.25 (8 analysts), implying a +206.7% move over the next 12 months. The stock is currently 22% below its 52-week high of $11.85, remaining 10.6% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 85/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +206.7% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$9.21
Potential Downside
0%
Whystock Fair Value$9.21
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus8 analysts
Mean target$28.25+206.7%
Range$19.00 – $50.00
Fundamentals
MeiraGTx Holdings plc, a clinical-stage genetic medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degene...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$869.60M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.24
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
207.35%
Volume
Today's trading volume
570,969
Recent News
Can MeiraGTx Holdings PLC (MGTX) Stock Double? Cash Runway Offers a Hint
MeiraGTx Holdings PLC (NASDAQ:MGTX) is one of the best gene therapy stocks to buy in 2026. The stock has gained around 25% year-to-date and soared more than 95% over the past year. Looking ahead, analysts believe the stock could explode more than 100% in the next 12 months as MeiraGTx advances its various therapy programs. […]
Here's What Analysts Are Forecasting For MeiraGTx Holdings plc (NASDAQ:MGTX) After Its First-Quarter Results
MeiraGTx Holdings plc ( NASDAQ:MGTX ) missed earnings with its latest first-quarter results, disappointing...
MeiraGTx Holdings PLC (MGTX) Reports Q1 Loss, Lags Revenue Estimates
MeiraGTx (MGTX) delivered earnings and revenue surprises of -32.56% and -81.10%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Will Alector (ALEC) Report Negative Q1 Earnings? What You Should Know
Alector (ALEC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Enanta Pharmaceuticals (ENTA) Moves 5.3% Higher: Will This Strength Last?
Enanta Pharmaceuticals (ENTA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.